Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.
about
Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditisHigh-throughput sequencing of islet-infiltrating memory CD4+ T cells reveals a similar pattern of TCR Vβ usage in prediabetic and diabetic NOD miceCombination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.Antigen-specific therapeutic approaches in Type 1 diabetesMAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD miceFollowing the fate of one insulin-reactive CD4 T cell: conversion into Teffs and Tregs in the periphery controls diabetes in NOD mice.Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model.Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseasesAntigen-specific therapy against type 1 diabetes: mechanisms and perspectives.CD4 T cell differentiation in type 1 diabetes.Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2.Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs.A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis.Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice.Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers.
P2860
Q34205503-5FCDDDD6-289F-4FE6-A0CA-737CF1025815Q34244112-071F43E6-595D-451A-9526-151B3B25AA5AQ34355286-0A16598C-C3A1-46E5-B117-91286AE5C60BQ34583970-92B31978-9D4C-43AE-BFD5-2F53BEEBBC5FQ34819379-9A3AB549-9EA7-4792-9589-3959F2C48DE1Q35022826-73D7455E-6235-46AE-BCC7-9681D7249F3DQ35665104-610112E8-0E83-4A95-9B5B-C2B75E68AFE6Q35762883-8A9BCE7B-9727-4438-8AF5-995856E87C94Q35891738-A96D0BD3-54FB-4997-8869-A4F2D64F287BQ35902920-7AB45A10-C691-4687-9809-414DFDCC4C37Q36637650-0F8908D6-EE65-49F8-B73D-A13010410B84Q36913149-69EA59F4-E87C-4F3A-915A-7664BAB6EFF1Q37105550-3EEAF663-263C-4784-9796-05396367E2DCQ38184646-3AB39FBF-5818-41DE-BBBE-BB5320F256DDQ38535279-A42B128E-F074-474E-A25E-7720C17DC0FCQ39665315-41406290-9773-460B-8606-B0EC35A660AFQ40895314-A5A85C44-A400-4BBB-867D-6B1815A1D4C7Q40967621-F79C5FA3-5492-4461-AB2D-45DAD528599FQ41275399-4496DD29-3C33-4A0F-92C0-81E16F927CF4Q47617033-52D3A3F5-16C8-4689-81B1-0A20180D133CQ55224664-E04639E7-DDB6-40BE-AFB4-4BF8B4A17E2B
P2860
Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@ast
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@en
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@nl
type
label
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@ast
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@en
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@nl
prefLabel
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@ast
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@en
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@nl
P2093
P2860
P1433
P1476
Subcutaneous insulin B:9-23/IF ...... ce through IL-10 and IFNgamma.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-010-1777-X
P577
2010-05-20T00:00:00Z
P5875
P6179
1007466098